Seoulin Bioscience Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
March 10, 2022 at 08:04 am
Share
Seoulin Bioscience Co.,Ltd. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was KRW 304.1 million compared to KRW 449.09 million a year ago. Net income was KRW 15,589.41 million compared to KRW 4,892.55 million a year ago.
Basic earnings per share from continuing operations was KRW 1,858.8159 compared to KRW 582.7845 a year ago. Diluted earnings per share from continuing operations was KRW 1,858.8159 compared to KRW 582.7845 a year ago. Basic earnings per share was KRW 1,905.3742 compared to KRW 597.3817 a year ago.
Seoulin Bioscience Co., Ltd is a Korea-based company engaged in the developing and manufacturing of basic equipment for bio research. The Company mainly engages in research and development of reagents, such as deoxyribonucleic acid (DNA) chips, which are used for gene therapy, clinical diagnosis, organs transplantation and biopsy; stem cells, which are used for treatment of incurable diseases, Alzheimer disease and others, and next-generation biotechnology drugs. The company supplies its products under the brand name MyLab. It also imports bio research equipment from Thermo Fisher, Affymetrix, Sarstedt and others, and markets in the domestic market. In addition, the Company engages in the real estate rental business.
SEOULIN BIOSCIENCE CO.,LTD. 
